Compare DexCom, Inc. (DXCM) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TeraWulf Inc — how do they compare? DexCom, Inc. trades at $84.08 (market cap $31.86B), while TeraWulf Inc trades at $13.76 (market cap $6.81B). The key difference: DexCom, Inc. is far larger — about 4.7× TeraWulf Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and TeraWulf Inc for 17 Days on average.
| DXCM | WULF | |
|---|---|---|
Market Cap | $31.86B | $6.81B |
Volume | 3,607,070 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $92.34 | $28.98 |
52-Week Low | $54.84 | $10.99 |
Typical Hold Time | 62 Days | 17 Days |
Enterprise Value | $31.32B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
TeraWulf (WULF) trades at $13.73, down 4.65% today, amid a challenging fundamental backdrop with significant losses and negative margins. The stock shows technical bearish signals with moving averages indicating selling pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights the company's pivot to AI data center operations, with positive analyst coverage despite poor financial performance.
While analyst consensus remains strongly bullish with a $34.92 price target, fundamental weaknesses including negative net income margin of -1,179.94% and high valuation ratios present substantial risks. The company's transition to AI hosting offers growth potential but requires careful monitoring of cash flow sustainability and competitive positioning in the evolving data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
